Ameritas Investment Partners’s Prelude Therapeutics PRLD Stock Holding History

Ameritas Investment Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-819	Closed	-$629	–	3307
2025 Q1	$629	Hold	819	–	–	﹤0.01%	3119
2024 Q4	$1.04K	Hold	819	–	–	﹤0.01%	3118
2024 Q3	$1.7K	Hold	819	–	–	﹤0.01%	3103
2024 Q2	$3.12K	Hold	819	–	–	﹤0.01%	3072
2024 Q1	$3.88K	Hold	819	–	–	﹤0.01%	2980
2023 Q4	$3.5K	Hold	819	–	–	﹤0.01%	3016
2023 Q3	$2.53K	Hold	819	–	–	﹤0.01%	3051
2023 Q2	$3.69K	Buy	+819	New	+$4.89K	﹤0.01%	3062
2022 Q2	–	Sell	-769	Closed	-$5K	–	3198
2022 Q1	$5K	Hold	769	–	–	﹤0.01%	2973
2021 Q4	$10K	Hold	769	–	–	﹤0.01%	2900
2021 Q3	$24K	Hold	769	–	–	﹤0.01%	2603
2021 Q2	$22K	Hold	769	–	–	﹤0.01%	2689
2021 Q1	$33K	Hold	769	–	–	﹤0.01%	2319
2020 Q4	$55K	Buy	+769	New	+$38.2K	﹤0.01%	1937

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ameritas Investment Partners's PRLD Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 819 shares — an estimated $629 sold.

Ameritas Investment Partners first reported a position in PRLD in Q4 2020 and held it in 14 quarters. The position peaked at $55K in Q4 2020. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

Ameritas Investment Partners reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 819 Prelude Therapeutics shares in Q2 2025, an estimated $629.
Ameritas Investment Partners first reported a position in Prelude Therapeutics in Q4 2020 and held it in 14 quarters.
Ameritas Investment Partners's Prelude Therapeutics position peaked at $55K in Q4 2020.
50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.